181 related articles for article (PubMed ID: 27299937)
1. Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.
Zhou D; Bui K; Sostek M; Al-Huniti N
CPT Pharmacometrics Syst Pharmacol; 2016 May; 5(5):250-7. PubMed ID: 27299937
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol.
Bui K; Zhou D; Sostek M; She F; Al-Huniti N
J Clin Pharmacol; 2016 Aug; 56(8):1019-27. PubMed ID: 26678015
[TBL] [Abstract][Full Text] [Related]
3. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.
Bui K; Zhou D; Xu H; Floettmann E; Al-Huniti N
Clin Pharmacokinet; 2017 Jun; 56(6):573-582. PubMed ID: 28035588
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
7. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Einolf HJ; Zhou J; Won C; Wang L; Rebello S
Drug Metab Dispos; 2017 Apr; 45(4):361-374. PubMed ID: 28122787
[TBL] [Abstract][Full Text] [Related]
8. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol.
Bui K; She F; Zhou D; Butler K; Al-Huniti N; Sostek M
J Clin Pharmacol; 2016 Apr; 56(4):497-505. PubMed ID: 26248047
[TBL] [Abstract][Full Text] [Related]
9. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715
[TBL] [Abstract][Full Text] [Related]
11. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
12. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.
Al-Huniti N; Chapel S; Xu H; Bui KH; Sostek M
Br J Clin Pharmacol; 2016 Jan; 81(1):89-100. PubMed ID: 26317320
[TBL] [Abstract][Full Text] [Related]
14. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
15. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
[TBL] [Abstract][Full Text] [Related]
16. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.
Bui K; Birmingham B; Diva U; Berger B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):420-427. PubMed ID: 28127938
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
18. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
[TBL] [Abstract][Full Text] [Related]
19. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):442-8. PubMed ID: 27137716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]